Most Read Articles
04 Oct 2018
A week of preoperative oral antibiotics prior to percutaneous nephrolithotomy does not appear to confer any benefit in patients at low risk for infectious complications, suggests a recent study. Perioperative antibiotics according to the American Urological Association (AUA) Best Practice Statement is deemed sufficient.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.

Nebivolol exerts beneficial effect on small artery elasticity

05 Feb 2018

Treatment with nebivolol in asymptomatic individuals with prehypertension or borderline blood pressure (BP) provides superior improvements in small artery function compared with atenolol in spite of their similar BP-lowering effect, a study has found.

A total of 60 individuals with prehypertension or borderline BP and abnormal small artery elasticity (SAE) had been randomized to receive placebo (n=22), nebivolol 5/10 mg/day (n=20) or atenolol 25/50 mg/day (n=18) once daily for 9 months.

All participants underwent assessment with multiple tests, including large and small artery elasticity, resting and treadmill exercise BP, carotid intimal-media thickness, retinal vascular photography, microalbuminuria, electrocardiography, echocardiography, and plasma B-type natriuretic peptide level. Scores for each test (normal [0], borderline [1] or abnormal [2]) were added to determine the total disease score (DS).

At 9 months, mean DS decreased significantly from baseline with nebivolol (from 4.3 to 2.8; p<0.007) and atenolol (from 5.4 to 3.5; p=0.0006) but only numerically with placebo (from 5.2 to 4.5; p=0.18).

Of note, nebivolol produced an increase in SAE (from 6.0 to 8.4 ml/mmHg × 100; p=0.0001). On the other hand, no significant change in SAE was observed with atenolol or placebo.

Researchers underscored the importance of the beneficial effect of nebivolol on SAE in the early treatment of asymptomatic cardiovascular disease (CVD). Given that SAE is a marker for endothelial dysfunction, the favourable effects of nebivolol on endothelial function suggest that the drug may slow progression of early CVD more effectively atenolol.

A number of individuals with normal BP values may be at high risk of developing CVD events, and this population are generally not treated with antihypertensive drugs, although many develop morbid events without manifesting hypertensive BP readings. In these patients, therapy must be targeted at vascular and cardiac protection rather than BP reduction. [Lancet 2016;387:957-967]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2018
A week of preoperative oral antibiotics prior to percutaneous nephrolithotomy does not appear to confer any benefit in patients at low risk for infectious complications, suggests a recent study. Perioperative antibiotics according to the American Urological Association (AUA) Best Practice Statement is deemed sufficient.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.